Seeking Alpha

Transcept Pharmaceuticals (TSPT +5.9%) jumps on an upgrade from Lazard. The firm expects FDA...

Transcept Pharmaceuticals (TSPT +5.9%) jumps on an upgrade from Lazard. The firm expects FDA approval in July for its Intermezzo insomnia treatment, designed to treat intermittent waking vs. peers Ambien (SNY) and Lunesta (SEPR), which require at least seven hours for heavy sleep.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|